Administration of AVP — Competitive Intelligence Brief

Administration of AVP (Administration of AVP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor agent. Area: Critical Care / Intensive Care Medicine.

phase 3 Vasopressor agent V1 and V2 vasopressin receptors Critical Care / Intensive Care Medicine Small molecule

Target snapshot

Administration of AVP (Administration of AVP) — Assistance Publique - Hôpitaux de Paris. AVP is an arginine vasopressin analog that acts as a vasopressor agent to increase blood pressure and peripheral vascular resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of AVP TARGET	Administration of AVP	Assistance Publique - Hôpitaux de Paris	phase 3	Vasopressor agent	V1 and V2 vasopressin receptors
Vasopressin, Arginine	Vasopressin, Arginine	Lars Wiuff Andersen	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptors (V1a, V1b, V2)
Vasopressin intravenous infusion	Vasopressin intravenous infusion	University of Sao Paulo	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptor V1a, V1b, and V2
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)
Intracervical injection of Vasopressin	Intracervical injection of Vasopressin	Prisma Health-Upstate	marketed	Vasopressor agent	V1 vasopressin receptor
Angiotensin II Infusion	Angiotensin II Infusion	Massachusetts General Hospital	marketed	Vasopressor agent	Angiotensin II receptor (AT1 and AT2)
vasopressin - early initiation	vasopressin - early initiation	The Cleveland Clinic	marketed	Vasopressor agent	Vasopressin receptor (V1 and V2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor agent class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Hospital do Coracao · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. Prisma Health-Upstate · 1 drug in this class
5. The Cleveland Clinic · 1 drug in this class